Advertisement

Document › Details
Corlieve Therapeutics SAS. (1/21). "Press Release: Corlieve Therapeutics Awarded 1M Euro in Deeptech Financing from Bpifrance".
![]() |
Region | France |
![]() |
Organisation | Corlieve Therapeutics SAS |
Organisation 2 | Bpifrance | |
Group | France (govt) | |
![]() |
Product | gene therapy |
Product 2 | business development (state/region) | |
![]() |
Index term | Corlieve Therapeutics–France (govt): grant, 202101 Deeptech award €1m from Bpifrance |
![]() |
Person | Porter, Richard (Corlieve 201911– CEO + Co-Founder before Therachon + Roche + Shire + Vernalis + Astra) |
In January 2021, Corlieve Therapeutics announced that it has been awarded 1M euro in Deeptech financing from Bpifrance, which follows the company’s recent seed funding round announced in November 2020. The Deeptech plan, initiated by the French government and deployed by Bpifance since 2019, aims to boost highly innovative and breakthrough projects emerging from fundamental research with attractive dedicated financing tools.
“We’re very proud to win this Deeptech financing award from Bpifrance, who share our commitment to innovation and to delivering novel therapeutic options to patients in France, the EU, and across the globe,” said Richard Porter, Ph.D., Chief Executive Officer of Corlieve.
About Bpifrance
Bpifrance is the French national investment bank. It finances businesses – at every stage of their development – through loans, guarantees, equity investments and export insurances. Bpifrance also provides extra financial services, such as training and consultancy to help entrepreneurs meet their challenges.
www.bpifrance.com.
About Corlieve Therapeutics
Corlieve Therapeutics is a biotechnology company focused on bringing novel therapeutic options to patients with severe neurological disorders. The lead project is targeting aberrantly expressed kainate receptors in the hippocampus of patients with TLE using a gene therapy approach. For more information, please visit www.corlieve.com and engage with us on LinkedIn.
Record changed: 2024-03-30 |
Advertisement

More documents for Corlieve Therapeutics SAS
- [1] Uniqure N.V.. (6/22/21). "Press Release: Uniqure to Acquire Corlieve Therapeutics and Advance its Gene Therapy Program to Treat Temporal Lobe Epilepsy (TLE)". Lexington, MA, Amsterdam & Paris....
- [2] Corlieve Therapeutics SAS. (11/2/20). "Press Release: Corlieve Therapeutics SAS Closes Seed Financing to Develop Therapies for Severe Neurological Conditions". Paris....
- [3] NovaGo Therapeutics AG. (9/21/20). "Press Release: NovaGo Therapeutics Appoints Ian Metcalfe as CEO". Schlieren....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement

» top